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ABSTRACT
Many Member States of the European Union (EU) currently monitor antimicrobial resistance in zoonotic
agents, including Salmonella and Campylobacter. According to Directive 2003 ⁄ 99 ⁄EC, Member States shall
ensure that the monitoring provides comparable data on the occurrence of antimicrobial resistance. The
European Commission asked the European Food Safety Authority to prepare detailed specifications for
harmonised schemes for monitoring antimicrobial resistance. The objective of these specifications is to
lay down provisions for a monitoring and reporting scheme for Salmonella in fowl (Gallus gallus), turkeys
and pigs, and for Campylobacter jejuni and Campylobacter coli in broiler chickens. The current
specifications are considered to be a first step towards a gradual implementation of comprehensive
antimicrobial resistance monitoring at the EU level. These specifications propose to test a common set of
antimicrobial agents against available cut-off values and a specified concentration range to determine
the susceptibility of Salmonella and Campylobacter. Using isolates collected through programmes in which
the sampling frame covers all epidemiological units of the national production, the target number of
Salmonella isolates to be included in the antimicrobial resistance monitoring per Member State per year is
170 for each study population (i.e., laying hens, broilers, turkeys and slaughter pigs). The target number
of Campylobacter isolates to be included in the antimicrobial resistance monitoring per Member State per
year is 170 for each study population (i.e., broilers). The results of the antimicrobial resistance
monitoring are assessed and reported in the yearly national report on trends and sources of zoonoses,
zoonotic agents and antimicrobial resistance.
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INTRODUCTION
The introduction of antimicrobial agents for use
in human clinical medicine and animal
husbandry has been an important achievement.
The first antimicrobial agents were introduced
during the 1930s, but unfortunately, emergence
of antimicrobial resistance has always fol-
lowed the introduction of new antimicrobial
compounds [1].
Modern food animal production uses large
amounts of antibiotics for disease control. This
provides favourable conditions for selection,
spread and persistence of antimicrobial-resistant
bacteria capable of causing infections in animals
and humans. During the last decade, there has
been an increase in awareness of the potential
problems that selection of antimicrobial resistance
among food-producing animals could cause for
human health. In addition, food animals and food
of animal origin are traded worldwide. This has
emphasised the need for global initiatives and
the establishment of standardised monitoring
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systems for determining the occurrence of resis-
tance among food animals in all countries [2–5].
Recommendations concerning antimicrobial
agents to be included in susceptibility testing,
the methodology to use and suggestions for
breakpoints have been published previously.
However, detailed specifications on the proce-
dures to follow, the antimicrobial agents to
include and the breakpoints ⁄ cut-off values to
use have not been agreed. There is a considerable
lack of standardisation among the monitoring
programmes that have already been established,
making comparison among countries difficult
[5,6]. According to Article 7 of Directive
2003 ⁄ 99 ⁄EC on the monitoring of zoonoses and
zoonotic agents, Member States must establish a
monitoring system that provides comparable data
on the occurrence of antimicrobial resistance in
zoonotic agents originating from animals, food
and feed and, insofar as they present a threat to
public health, other agents [7].
To address this need, in 2006 the European
Commission asked the European Food Safety
Authority (EFSA) to prepare detailed specifica-
tions for harmonised schemes on monitoring
antimicrobial resistance. The EFSA convened a
working group under its Task Force on Zoonoses
Data Collection, consisting of scientists with
expertise in epidemiology and microbiology,
and experience in monitoring antimicrobial resis-
tance, as well as staff from relevant European
institutions. The working group developed
detailed specifications for monitoring antimicro-
bial resistance in, initially, Salmonella and Cam-
pylobacter, to be used in all 27 Member States of
the European Union (EU) [8]. On the basis of
these specifications, the Commission adopted
Commission Decisions regarding the monitoring
of antimicrobial resistance in Salmonella and
Campylobacter [9,10].
This review considers the specifications for a
harmonised monitoring scheme of antimicrobial
resistance in Salmonella from fowl (Gallus gallus),
turkeys and pigs, and Campylobacter jejuni and
Campylobacter coli from broiler chickens. How-
ever, many aspects of the laboratory methodology
(susceptibility test methods, choice of antimicro-
bial agents and interpretive criteria), as well as
sample size, are applicable regardless of the
source of the isolate of a particular bacterial
species. The current specifications are considered
to be a first step towards a gradual implementa-
tion of comprehensive antimicrobial resistance
monitoring for different animal and bacterial
species.
ELEMENTS OF A MONITORING
SCHEME
Several issues need to be addressed when estab-
lishing a monitoring scheme, e.g., determining the
study population, bacterial species to be included,
sampling strategies, isolation procedures, number
of samples to be tested, susceptibility testing
methods, and data recording, computing and
reporting [4,6,11–13]. The following sections con-
sider detailed specifications for the following
elements: animal species and bacterial species;
study population; sampling plan; sample size;
detection, identification and storage of isolates;
methods for susceptibility testing; antimicrobial
agents to include; cut-off values to use; and data
collection and reporting.
Animal and bacterial species
Requirements exist to establish national control
programmes for Salmonella. These requirements
specify that EU targets for a reduction in Salmo-
nella prevalence should be established for flocks
of poultry and turkeys, and in herds of pigs [14].
Within these control programmes, food business
operators must have samples taken and analysed,
and official controls, including sampling schemes,
are required. This entails regular testing of the
total populations of these animal species, or of
representative subsets, in all Member States. It is
opportune to use these isolates for the purposes of
antimicrobial resistance monitoring, as the under-
lying schemes through which they are collected
are already harmonised across Member States.
Study population
While it may be of interest to monitor antimicro-
bial resistance in various production phases, the
greatest benefit may result from focusing on those
populations to which the consumer is most likely
be exposed. This means that isolates from
broilers, turkeys and pigs should preferably be
collected close to or at slaughter, whereas isolates
from laying hens should be collected periodically
throughout the egg production cycle. For this
reason, the current specifications are limited to
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the production phases specified for the different
study populations in Table 1.
Sampling plan
Monitoring of antimicrobial resistance can be
based on isolates from clinical samples submitted
to a diagnostic laboratory, or on actively collected
isolates from healthy or diseased animals. Animal
pathogens are normally included because it is
important to observe trends in pathogenic organ-
isms. The selection of isolates from clinical infec-
tions will depend in most cases on the submission
of isolates from local veterinarians. This will
lower the value of these isolates in a surveillance
programme because of bias in the selection
criteria used over time, and because participation
varies among veterinarians. Some infections are
more likely to generate symptoms, and isolates
from such infections are more likely to be sent for
susceptibility testing. Furthermore, in many cases,
isolates are sent to a laboratory only after the
animals have received antimicrobial treatment,
and some veterinarians will send samples only
after they have observed treatment failure. Thus,
the data obtained from these isolates might
overestimate the occurrence of resistance.
To provide an unbiased estimate of the pro-
portion of resistance, the sampling frame should
cover all epidemiological units (flocks or hold-
ings) of the national production. This is achieved
most readily if isolates originate from national
control programmes in which the prevalence of
Salmonella is determined, and details on where
the sampling is to take place and the type of
material to collect are already fixed. The epide-
miological unit for laying hens, broilers and
turkeys is the flock, because most holdings
practice all-in-all-out production. For pigs, the
epidemiological unit is the holding, because
many farms do not practice strict all-in-all-out
production.
Sample size
The number of isolates to be tested should allow,
with predetermined accuracy, the calculation of
the proportion of resistance to a particular
antimicrobial agent in the Member States, and
the detection of changes in this proportion over
time. The target sample size may vary, depend-
ing on whether the sample size is calculated for
the purpose of estimating the proportion of
resistance or for the purpose of determining a
trend. In addition, the sample size differs greatly
according to the magnitude of the change that it
is desired to detect, or the accuracy of the
estimate and the initial resistance situation. If
resistance is already widespread, only a rela-
tively large decrease or increase in the propor-
tion of resistance is considered to be relevant.
However, for the detection of the initial emer-
gence of resistance, an increase of a few per cent
should be detectable.
Based on the assumptions of (i) an infinite
population size for the number of bacterial iso-
lates in each study population and Member State,
(ii) a 95% CI and a power of 80%, and (iii) 100%
sensitivity and specificity of the diagnostic test
(i.e., categorisation of isolates into susceptible or
resistant categories by means of antimicrobial
susceptibility testing), an adequate target number
of isolates from a public health perspective for
susceptibility testing ⁄ study population ⁄Member
State ⁄ year is 170. This sample size allows the
detection of a change of 15% in a setting with
widespread resistance (50% resistance) and an
increase of 5% in a setting with few pre-existing
resistant isolates (0.1% resistance), and provides
an accuracy of ±8% in the worst-case scenario of
50% resistance. If a linear trend exists within a
country, smaller changes in proportion can be
detected over time. Over a 3-year period of
continuous monitoring, an average 5% decrease
in the proportion of resistant isolates ⁄year can be
detected, starting from an initial proportion of
resistance of 50%, and an average increase of
2% ⁄year can be detected starting from an initial
proportion of resistance of 0.1% [8]. At the
aggregate European level, the monitoring pro-
gramme will be even more precise than this.
Thus, the monitoring programme will also pro-
vide valuable information on sub-populations
with a small sample size ⁄Member State, e.g., rare
Salmonella serovars.
Table 1. Study population and sampling plan (adapted
from Annex IIB of Regulation 2160 ⁄ 2003 ⁄EC)
Animal species Study population
Production phase at
primary production
Fowl
(Gallus gallus)
Flocks of laying hens Every 15 weeks during the
laying phase
Broiler flocks Animals leaving for slaughter
Turkeys All flocks Animals leaving for slaughter
Pigs Slaughter pig herds Animals leaving for slaughter or
carcasses at slaughterhouse
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Detection, identification and storage of isolates
For isolation and confirmation of bacteria, vali-
dated methods need to be followed, as defined in
the national control programmes, which foresee
that Member States will store isolates for at least
2 years.
For Salmonella, all isolates selected for antimi-
crobial susceptibility testing should be identified
to the serovar level. For Salmonella Enteritidis and
Salmonella Typhimurium, it is recommended that
all isolates selected for antimicrobial susceptibility
testing are phage-typed to allow proper interpre-
tation of the observed frequencies of resistance.
For Campylobacter, all the isolates selected for
antimicrobial susceptibility testing should be iden-
tified to the species level. Monitoring is restricted to
C. jejuni and C. coli, which are the most important
species causing infections in humans.
Methods for susceptibility testing
To achieve optimum sensitivity for detection of
acquired resistance, it is proposed that epidemi-
ological cut-off values, rather than ‘clinical’
breakpoints, are used as interpretive criteria.
Disk-diffusion is not advocated for European
monitoring, because different methodologies are
used with different interpretive criteria, and
epidemiological cut-off values have not been
defined for disk-diffusion. In addition, the disk-
diffusion method does not guarantee reproduc-
ibility of results for Campylobacter spp. Therefore,
to improve the comparability of the data provided
by Member States, only quantitative data provid-
ing MIC values will be accepted.
For non-fastidious microorganisms, e.g., Salmo-
nella spp., the EUCAST and CLSI methods for
determining MICs have been accepted as inter-
national reference methods through CEN and
ISO. Dilution methods should be performed
according to these methods, as described in ISO
Standard 20776-1:2006 [15].
For Campylobacter spp., dilution methods
should be performed according to the methods
described by CLSI [16,17]. At present, the CLSI
recommendations are the only international stan-
dards giving guidance on broth microdilution
testing and quality assurance for Campylobacter
spp.
To control the quality and comparability of MIC
results, laboratories performing susceptibility
testing should participate successfully in
proficiency testing conducted regularly by the
Community Reference Laboratory for Antimicro-
bial Resistance.
Antimicrobial agents to include in resistance
monitoring programmes
Many different antimicrobial agents are currently
used in national monitoring programmes. Some
examples for Salmonella and Campylobacter spp.
are given in Tables 2 and 3, respectively. The five
national monitoring programmes listed for
Salmonella test a total of 36 different antimicrobial
agents or combinations. While each programme
includes between 12 and 19 antimicrobial agents,
only four agents are tested in all five programmes.
For Campylobacter spp., between six and 11 anti-
microbial agents are included, covering 17 differ-
ent antimicrobial agents or combinations, but only
two agents are tested in all five programmes. This
shows a clear need for harmonisation of monitor-
ing programmes.
Antimicrobial agents to be included in a
monitoring programme should provide valuable
information and should be selected to ensure
the highest possible sensitivity in detecting the
presence of different resistance mechanisms. In
many cases, antimicrobial resistance mecha-
nisms can be inferred by determining the MIC
of a given antimicrobial agent or groups of
agents. It is then possible, without further
testing, to infer which other antimicrobial agents
will probably be inactivated by the same resis-
tance mechanism [18,19]. In addition, some
types of resistance genes, e.g., those encoding
resistance to cephalosporins, might give a com-
plex pattern of resistance. In such cases, it is
advisable to choose the antimicrobial agent that
is most likely to detect resistance to the entire
group, and then to select resistant isolates for
further testing or research studies.
Thus, monitoring based on a relatively limited
number of antimicrobial agents can give informa-
tion about the likely resistance to a much broader
group of agents and ⁄ or information concerning
which isolates should be tested with additional
antimicrobial agents. The list of recommended
antimicrobial agents to be tested is given in
Table 4, together with concentration ranges to be
tested and interpretative criteria. Only the most
relevant antimicrobial agents are included, based
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on their relevance for human therapeutic use
and ⁄ or epidemiological relevance for monitoring
and ⁄ or detecting new resistance mechanisms of
public health importance.
Salmonella spp.
Aminoglycosides. It recommended that streptomy-
cin and gentamicin should be included, but
not neomycin, kanamycin or apramycin. Strepto-
mycin is considered to be an important antibiotic
to include in monitoring programmes for detect-
ing resistance in Salmonella spp. because it is used
as an indicator for the presence of the penta-
resistance phenotype of S. Typhimurium DT104
or DT104-like phenotypes. Because of the varia-
tions in phenotype, the wild-type susceptibility
distribution has not been defined by EUCAST;
it is therefore recommended that the resistance (R)
breakpoint of >32 mg ⁄L proposed by the
Concerted Action on Antibacterial Resistance in
Bacteria of Animal Origin (ARBAO) [20] should be
used to identify all highly-resistant isolates. The
resistance gene that encodes streptomycin resis-
tance in DT104 is aadA2. Variants of this gene are
known to occur in other serovars or phage types of
S. Typhimurium.
Gentamicin, which is related to kanamycin and
amikacin, is considered to be an important agent
for routine monitoring, as it is used in both
animals and humans for the treatment of serious
infections. Resistance is encoded by a variety of
genes encoding aminoglycoside acetylase (AAC),
aminoglycoside nucleotidyl transferase (ANT)
and aminoglycoside phosphorylase (APH) en-
zymes. Cross-resistance to other aminoglycosides
can occur, and this depends on the precise gene
present.
Neomycin is an aminoglycoside for which a
variety of resistance mechanisms exist, including
APH(2¢), APH(3¢¢), AAC(2¢) and AAC(6¢)-III, that
result in cross-resistance to other aminoglycosides.
Table 2. Antimicrobial agents included in different monitoring programmes for Salmonella
Antimicrobial group Antimicrobial agent
National monitoring programme
Common to
all five systemsDANMAP NARMS Japan MARAN CIPARS
Aminoglycosides Amikacin X X
Apramycin X X
Gentamicin X X X X X X
Kanamycin X X X
Neomycin X X
Spectinomycin X
Streptomycin X X X X
Aminopenicillins Ampicillin X X X X
Amoxycillin X
b-Lactamase inhibitor combinations Amoxycillin + clavulanic acid X X X
Cephalosporin (first generation) Cephalothin X X
Cephalosporins (third generation) Cefazolin X
Ceftiofur X X X X
Cefotaxime X
Ceftriaxone X X
Cefuroxime X
Cephamycins Cefoxitin X X
Carbapanems Imipenem X
Folate pathway inhibitors Sulphamethoxazole X X X
Sulphisoxazole X X
Trimethoprim X X
Trimethoprim + sulphonamides X X X
Macrolides Azithromycin X
Erythromycin X
Phenicols Chloramphenicol X X X X X X
Florfenicol X X
Polypeptides Colistin X X
Quinolones Ciprofloxacin X X X X
Enrofloxacin X
Ofloxacin X
Oxolinic acid X
Nalidixic acid X X X X X X
Tetracyclines Oxytetracycline X X X X X X
Other Destromycin X
Bicozamycin X
Olaquindox X
Total number of antimicrobial
agents included
17 19 19 12 15 4
DANMAP, Danish Integrated Antimicrobial Resistance Monitoring and Research Programme; NARMS, National Antimicrobial Resistance Monitoring System (USA);
MARAN, Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in The Netherlands; CIPARS, Canadian Integrated Program for Antimicrobial Resistance
Surveillance.
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Cross-resistance to kanamycin depends on the
precise gene present. Similarly, kanamycin is
related to gentamicin, tobramycin, amikacin and
netilmicin. Resistance is mediated by genes
encoding AAC(3), ANT(2¢¢)-I and APH. Cross-
resistance to other aminoglycosides can occur, but
also depends on the precise gene present. Neo-
mycin and kanamycin are not used currently for
the treatment of infections in humans, and the
mechanisms of resistance to these agents have no
application in the identification of specific clones
of Salmonella.
Apramycin is used for oral treatment of infec-
tions in pigs and calves. This agent is not used in
humans, and is not recommended for inclusion in
surveillance programmes, although cross-resis-
tance to other aminoglycosides, including genta-
micin, can occur [21].
Amphenicols. It is considered to be more impor-
tant to include chloramphenicol than florfenicol.
Chloramphenicol has been prohibited for use in
food-producing animals in the EU since
1994 [22], but substantial resistance levels are
Table 3. Antimicrobial agents included in various monitoring programmes for Campylobacter spp.
Antimicrobial group Antimicrobial agent
National monitoring programme
Common to all five systemsDANMAP NARMS SVARM MARAN CIPARS
Aminoglycosides Gentamicin X X X X
Neomycin X
Streptomycin X X
Aminopenicillins Ampicillin X
Amoxycillin X
Folate pathway inhibitors Trimethoprim + sulphonamides X
Sulphamethoxazole X
Lincosamides Clindamycin X X
Macrolides Azitromycin X X
Erythromycin X X X X X X
Phenicols Chloramphenicol X X X
Quinolones Ciprofloxacin X X X X
Enrofloxacin X
Nalidixic acid X X X X X X
Tetracyclines Oxytetracycline X X X X
Doxycycline X
Metronidazole X
Total number of antimicrobial agents included 7 8 6 11 8 2
DANMAP, Danish Integrated Antimicrobial Resistance Monitoring and Research Programme; NARMS, National Antimicrobial Resistance Monitoring System (USA);
MARAN, Monitoring of Antimicrobial Resistance and Antibiotic usage in Animals in The Netherlands; CIPARS, Canadian Integrated Program for Antimicrobial Resistance
Surveillance; SVARM, Swedish Veterinary Antimicrobial Resistance Monitoring.
Table 4. Antimicrobial agents sug-
gested for antimicrobial resistance
monitoring programmes
Antimicrobial agent
Epidemiological
cut-off value (mg ⁄L)
Advised optimum concentration
range to be tested (mg ⁄L)
Salmonella Cefotaxime 0.5 0.06–8
Nalidixic acid 16 2–256
Ciprofloxacin 0.06 0.008–8
Ampicillin 4 0.5–64
Tetracycline 8 0.5–64
Chloramphenicol 16 2–256
Gentamicin 2 0.25–32
Streptomycin 32b 2–256
Trimethoprima 2 0.25–32
Sulphonamides 256c 8–1024
Campylobacter jejuni Erythromycin 4 0.5–64
Ciprofloxacin 1 0.06–8
Tetracycline 2 0.125–16
Streptomycin 2 0.5–32
Gentamicin 1 0.125–16
Campylobacter coli Erythromycin 16 0.5–64
Ciprofloxacin 1 0.06–8
Tetracycline 2 0.125–16
Streptomycin 4 0.5–32
Gentamicin 2 0.125–16
aTrimethoprim is often used in combination with sulphonamides because of synergy in clinical treatment.
However, for susceptibility testing it is important to test and report both substances separately.
bBreakpoint recommended by the Concerted Action on Antibiotic Resistance in Bacteria of Animal Origin (ARBAO)
project.
cCLSI breakpoint.
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still reported in Enterobacteriaceae. Linkage of
resistance genes and co-selection may explain
this phenomenon. Cross-resistance to florfenicol
depends on the precise resistance gene present.
Genes encoding a chloramphenicol acetyl-
transferase enzyme confer resistance only to
chloramphenicol, while the floR gene encodes
resistance to both substances [23]. It is re-
commended that chloramphenicol should be
included in surveillance programmes.
Florfenicol is also considered to be an impor-
tant agent for monitoring purposes, as the floR
gene is part of the multidrug resistance gene
cluster in S. Typhimurium DT104. However, all
isolates resistant to florfenicol are also resistant to
chloramphenicol.
Extended-spectrum penicillins and b-lactamase
inhibitors. It is recommended to include ampicillin
rather than amoxycillin or b-lactams combined
with b-lactamase inhibitors. Ampicillin represents
the extended-spectrum aminopenicillins with
intrinsic activity against Enterobacteriaceae.
Cross-resistance to amoxycillin is complete,
although slight differences in potency exist. Ampi-
cillin and amoxycillin are inactivated by all
b-lactamases produced by Enterobacteriaceae,
including TEM-1 and SHV-1. Furthermore, ampi-
cillin is traditionally used as an indicator agent for
the presence of b-lactamases in Enterobacteriaceae.
Amoxycillin–clavulanic acid is a combination
of a broad-spectrum b-lactam and a b-lactamase
inhibitor that inhibits the hydrolytic activity of
b-lactamases and classical extended-spectrum
b-lactamases (ESBLs). Resistance detected in
routine monitoring gives limited additional infor-
mation and can be methodologically difficult to
detect because the resistant and susceptible pop-
ulations are close together in terms of MICs.
Cephalosporins. Of the large variety of generations
and compounds available, it is suggested that
cefotaxime should be used for routine monitoring
of resistance in Salmonella.
Cephalothin is a first-generation cephalosporin
with an identical spectrum of antimicrobial activ-
ity to the broad-spectrum aminopenicillins. Ceph-
alothin is inactivated by all types of b-lactamases
produced by Enterobacteriaceae, including TEM-1
and SHV-1. Therefore, the inclusion of cephalothin
provides no added value over the inclusion of
ampicillin.
Third-generation cephalosporins are important
drugs for the treatment of systemic infections,
including those caused by Salmonella in humans,
especially children. Thus, bacteria that produce
ESBLs are considered to be a major public health
threat. The establishment of optimum phenotypic
testing systems for sensitive, specific and rapid
detection of ESBLs is therefore a very important
component of routine monitoring programmes
[24].
Escherichia coli and Salmonella isolates resistant
to oxyiminocephalosporins because of the pro-
duction of ESBLs have emerged worldwide, and a
number of different ESBL genes, e.g., the blaSHV,
blaTEM, blaCTX and blaCMY gene families, have been
identified [25–28]. Resistant isolates are found in
bacteria from infections in humans, as well as in
production and companion animals.
Different ESBLs show varying degrees of activ-
ity against the different cephalosporins. Thus, the
MICs for ESBL-producing isolates might vary
considerably, depending on the b-lactamase and
the cephalosporin tested. For routine surveillance
purposes, it is essential to use a cephalosporin
that will detect ESBL-producing isolates with
high sensitivity and specificity, using the most
optimal breakpoints. The CLSI has recommended
a number of different cephalosporins (cefpodox-
ime, ceftazidime, aztreonam, cefotaxime, ceftriax-
one) for initial screening, and also states that the
use of more than one cephalosporin will increase
the sensitivity of screening. However, the break-
points recommended by the CLSI have been
criticised. The UK Health Protection Agency
recommends the use of cefotaxime–ceftazidime
or cefpodoxime in its published guidance for
diagnostic laboratories [29]. Several cephalospo-
rins have been approved for use in food animals
and pets. The value of these veterinary cephalo-
sporins, e.g., cefoperazone, cefquinome and
ceftiofur, for detection of ESBLs is not yet
well-defined.
Testing for cefpodoxime resistance will result
in a large number of false-positive isolates [30].
Thus, although this cephalosporin is very sensi-
tive for detecting almost all ESBL-producing
isolates, it might give a false high prevalence for
cephalosporin resistance, and is thus of limited
value in routine monitoring. Ceftazidime, to-
gether with cefpodoxime, is considered to be the
best substrate for most TEM- and SHV-derived
ESBLs [19,24]. Cefotaxime is a good substrate for
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the CTX-M enzymes, which are the ESBLs that are
currently most common, whereas ceftazidime is a
poor substrate and gives a large number of false-
positive results. Other cephalosporins, including
the veterinary cephalosporins, might be as effi-
cient as cefotaxime in detecting ESBLs, but such
data are not currently available.
Quinolones. It is recommended that both nalidixic
acid and ciprofloxacin should be included in
susceptibility testing programmes. Compared
with ciprofloxacin, enrofloxacin is slightly less
potent, and a CLSI resistance breakpoint for
canine and feline enteric bacilli has been set at
‡4 mg ⁄L. Neither the epidemiological cut-off
value for enrofloxacin nor clinical breakpoints
for Enterobacteriaceae have been defined by
EUCAST. Furthermore, ciprofloxacin is used in
human medicine as the first-choice drug for
antimicrobial therapy of Salmonella infections in
patients at risk. Therefore, it is advised to use
ciprofloxacin rather then enrofloxacin for moni-
toring purposes, since the latter is used mostly in
veterinary medicine.
Until recently, chromosomal mutations in dif-
ferent genes involved in DNA transcription and
replication were considered to be the main mech-
anisms of quinolone resistance in Enterobacteria-
ceae. A single point mutation can mediate full
resistance to the first-generation agent nalidixic
acid, and reduced susceptibility to ciprofloxacin
and other fluoroquinolones. However, a new
transferable resistance mechanism was described
in Klebsiella pneumoniae in 1998 [31]. The respon-
sible gene, qnrA, encodes a protein that blocks the
action of fluoroquinolones. Two other qnr genes
(qnrB and qnrS) and a number of different
variants have subsequently been identified. These
resistance genes have been detected in several
species, including Salmonella enterica [32–34]. The
presence of the qnr genes alone does not neces-
sarily mediate full resistance to nalidixic acid, and
thus the use of only nalidixic acid to screen for
fluoroquinolone resistance is unreliable. Low-
level fluoroquinolone resistance is difficult to
detect in routine diagnostic laboratories, and such
isolates might easily be considered susceptible,
especially when using disk-diffusion methods.
Another mechanism of transferable quinolone
resistance was reported in 2006 [35]. The cr
variant of the aac(6¢)Ib gene encodes an AAC that
confers resistance to ciprofloxacin by N-acetyla-
tion of its piperazinyl amine. This variant has two
amino-acid changes, W102R and D179Y, which
together enable this aminoglycoside resistance
mechanism to also modify ciprofloxacin. This
new resistance mechanism may be very common,
and the limited number of reports to date prob-
ably reflects the fact that this gene has only
recently been discovered. The aac(6¢)Ib-cr gene
appears not to encode resistance to enrofloxacin,
but the activity of this resistance mechanism
against other veterinary fluoroquinolones and
nalidixic acid is currently unknown.
Folate synthesis pathway inhibitors. Sulphamethox-
azole and trimethoprim are recommended for
separate use in routine monitoring. Resistance to
sulphonamides is important for epidemiological
purposes, e.g., the detection of particular types of
Salmonella, including S. Typhimurium DT104. The
sulphonamide resistance genes that have been
identified in Salmonella encode resistance to all
known sulphonamides. Thus, sulphamethoxazole
is commonly used as a single representative of the
sulphonamide class in a monitoring programme.
Trimethoprim is often used in therapy and is
frequently tested in combination with sulphona-
mides because of apparent synergy between these
agents. These agents are often prescribed as a
combination (co-trimoxazole); therefore, when
monitoring resistance, these agents should be
tested individually because isolates are only resis-
tant to the combination if they are resistant to both
trimethoprim and sulphonamides.
Tetracyclines. Tetracycline should be used for
monitoring purposes as a representative of this
class of agents, which includes the related sub-
stances oxytetracycline, chlortetracycline, doxycy-
cline and minocycline. Resistance is encoded by
tet genes that result in active efflux of tetracycline
from the bacterial cell. Although differences in
antimicrobial potency exist among the agents in
this class, cross-resistance is complete, with the
exception of minocycline.
Campylobacter spp.
Macrolides. It is recommended to include eryth-
romycin as the representative agent for the
macrolides. Macrolides (erythromycin, clarithro-
mycin, azithromycin) are considered to be the
first-choice drugs for therapy of human infections
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caused by Campylobacter spp. Acquired resistance
is caused by single point mutations in the rDNA,
resulting in cross-resistance among the different
macrolides [36]. Macrolides are also commonly
used to treat food animals, and resistance to
macrolides has been reported, predominantly in
C. coli [37–39]. Erythromycin is commonly used in
test panels.
Quinolones. It is recommended that only cipro-
floxacin should be included in monitoring pro-
grammes for Campylobacter spp. Resistance to
quinolones and fluoroquinolones is caused by a
single point mutation in the gyrA gene, resulting
in resistance to both substances [36]. However,
isolates showing resistance to fluoroquinolones,
but not to nalidixic acid, have been reported.
Because intermediately-resistant sub-populations
of Campylobacter spp. do not exist, nalidixic acid
and ciprofloxacin are equally sensitive for the
detection of acquired resistance if epidemiological
cut-off values are used. Ciprofloxacin is particu-
larly relevant because of its high level of use in the
treatment of human infections.
Tetracyclines. The inclusion of tetracycline in
monitoring programmes for Campylobacter spp.
is relevant. Tetracyclines are considered to be
alternative agents for treatment of campylobact-
eriosis, and acquired resistance has been ob-
served. Resistance in Campylobacter spp. is
encoded by tet(O), which is a gene that encodes
a ribosomal protection protein [36].
Aminoglycosides. Streptomycin and gentamicin
should be tested as representatives of the amino-
glycoside class. Resistance to aminoglycosides in
Campylobacter spp. is mediated by genes encoding
APH and ANT enzymes [36]. Streptomycin resis-
tance can be used as an indicator for acquired
resistance genes and can give useful epidemio-
logical information. Aminoglycosides adminis-
tered by the intravenous route, e.g., gentamicin,
are the only alternative to macrolides and fluoro-
quinolones for systemic infections caused by
Campylobacter spp. [40].
b-Lactams. Extended-spectrum penicillins and
cephalosporins are not used for therapy of Cam-
pylobacter infections in humans, and are therefore
considered to be of low priority for surveillance
purposes.
Cut-off values
EUCAST has developed interpretive criteria for
classification of resistance to a variety of com-
pounds, based on wild-type MIC distributions
(http://www.eucast.org). The procedure for
developing epidemiological cut-off values has
been described previously [13,41,42]. The epide-
miological cut-off value is the highest MIC value
of the wild-type population (WT) that is appro-
priate to detect biological resistance, expressed as
WT £X mg ⁄L. EUCAST collects MIC data from as
many different sources as possible. These data are
collated into a single large distribution and a cut-
off value is proposed. An example is given in
Fig. 1, which shows MIC data for 1424 C. jejuni
and 2087 C. coli isolates from 17 different data
sources. Fig. 1 also shows why different cut-off
values are proposed for different species in some
cases. Qualitative results should be reported as
susceptible (S) or resistant (R), expressed as
S £X mg ⁄L or R >X mg ⁄L.
EUCAST has not proposed cut-off values for
streptomycin and sulphamethoxazole for use
with Salmonella, as tests of isolates with known
streptomycin resistance genes in different centres
have revealed a large number of deviations [43].
A cut-off value of R >32 mg ⁄L will probably
identify all highly-resistant isolates, but does not
exclude the possibility that isolates with acquired
resistance genes could be missed when using
these criteria.
It has been suggested that the concentration
range for a particular antimicrobial agent should
include the susceptible wild-type population and
at least four concentrations above the cut-off
values (Table 4). Most MIC determinations are
performed in microtitre plates, in which the
format means that the range would consist of a
minimum of eight two-fold dilutions. On occa-
sions, wider ranges are advised in order to detect
high-level resistance (e.g., to ciprofloxacin). The
objective of the relatively wide range is to detect
isolates with acquired resistance with optimum
sensitivity by including the wild-type susceptible
population within this range.
Data collection and reporting
Data should be collected and evaluated at the
national level, and should also be evaluated
centrally in order to make comparisons among
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countries. In many cases, data are reported only
as susceptible or resistant. However, for the
purpose of a continuous monitoring programme,
it would be optimal if data were reported as MICs
to allow comparisons over time, even if break-
points are changed.
Resistance to some antimicrobial agents can be
associated with particular Salmonella serovars or
phage types. MIC distributions for S. Typhimuri-
um and S. Enteritidis should be reported sepa-
rately because of their public health significance,
and because these serovars are likely to be
detected relatively frequently in many countries.
Clonal spread of resistant Salmonella serovars or
phage types is an important phenomenon in some
countries. S. Typhimurium and S. Derby should
be reported separately for pigs, as they occur at a
reasonably high prevalence in pigs in many
countries, and these data may also provide some
additional information concerning the relative
antimicrobial selective pressures being exerted
on the study populations. The other serovars may
be grouped together and reported for each study
population separately.
There are marked differences in the prevalence
of resistance shown by C. jejuni and C. coli to
different antimicrobial agents, and it is therefore
inappropriate to report both species together.
Reporting multiple resistance is of importance,
and it is therefore recommended that reports
should include information concerning the num-
ber of fully susceptible isolates and the number of
isolates resistant to one, two, three, four and more
than four agents. Results for additional antimi-
crobial agents should not be reported or included
in resistance profiles in order to ensure a fair
comparison of resistance data and the number of
multidrug-resistant isolates among countries.
Only resistance to different antimicrobial agents
with unrelated resistance mechanisms should be
reported. Thus, it is recommended to include data
concerning resistance to ciprofloxacin, but not
nalidixic acid, in the resistance profiles. For
Salmonella, it is also suggested that the number
of isolates with the penta-resistance (ACSSuT)
phenotype should be reported separately. It is
also recommended that the serovar and phage
type of these isolates should be reported.
DISCUSSION
National antimicrobial resistance monitoring pro-
grammes have now been implemented in a
number of countries worldwide. Most of these
programmes focus on pathogenic bacteria, e.g.,
Salmonella, and some also report data concerning
resistance in indicator bacteria isolated from
healthy animals. Since these programmes are not
coordinated centrally, they differ in the method-
ology used and the antimicrobial agents tested. In
the EU, based on the specifications developed by
the EFSA and subsequently adopted by the
Commission and Member States, a harmonised
monitoring programme will come into place
during 2008. In conjunction with the help of a
continuous external quality control scheme put in
force following the appointment of a Community
Reference Laboratory for Antimicrobial Resis-
tance, this should enable the centralised collection
of comparable antimicrobial resistance data of
good quality. The use of the current standards
will be evaluated during the years to come, and it
is likely that changes may be proposed as the
standards are used and new data become avail-
able.
The standards proposed in the Commission
Decisions are binding for all EU Member States,
but obviously not for countries in the rest of the
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Fig. 1. MIC distributions of erythromycin for Campylobac-
ter coli and Campylobacter jejuni (data obtained from
EUCAST; available at http://www.eucast.org).
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world. Different antimicrobial agents are tested
and different breakpoints are used in, e.g., the
National Antimicrobial Resistance Monitoring
System (NARMS) programme in the USA
(http://www.cdc.gov/narms/), which hinders
intercontinental comparisons. There is a need for
continuous international discussion on standards
for monitoring antimicrobial resistance.
At present, knowledge of antimicrobial resis-
tance in food animals is incomplete in many
Member States. Harmonised monitoring of anti-
microbial resistance will help to identify and
report emerging resistance problems at the earli-
est possible stage. In addition, knowledge of the
use of antimicrobial agents in different food
animal species is currently often unavailable or
incomplete. Such monitoring is needed to assess
the impact of antimicrobial use on the occurrence
of resistance, and to determine where, and for
which infections, most antimicrobial agents are
used. By implementing harmonised monitoring
schemes, Member States will make an important
step towards monitoring antimicrobial resistance
in bacteria of animal origin. It is hoped that,
together with improved harmonised collection of
data on the use of antimicrobial agents, it will be
possible to address important questions concern-
ing risks for humans and the most efficient
interventions.
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